Alexandra Kimball, MD, MPH

Kimball presented new data on MoonLake Immunotherapeutics’ sonelokimab and reflected on other HS updates presented at AAD 2026.

Many HS patients still require more aggressive or advanced treatments due to incomplete response to current options.

HS management is shifting toward earlier diagnosis and intervention to prevent long-term scarring and disability.

Alexandra Kimball, MD, FAAD, reviews late-breaking data at AAD on lutikizumab for hidradenitis suppurativa.